RESEARCH REPORT
In brief
How do you lead amidst change?
What if you could find opportunities to tie profitability to improvements in patients’ health, rewarding the innovation and better outcomes from New Science?
1. New Science is more important than ever
81%
New Science is projected to drive 81% of biopharma revenue growth and 61% of all revenues between 2021 and 2026, outpacing our previous forecast of 54% of all revenues from 2017-2022.
69%
expected higher average net present value (NPV) for New Science treatments versus traditional counterparts from 2022-2026.
76%
of all new deals intended to create new therapies in the last 5 years involved New Science treatments.
2. A new economic reality challenges profitability
3. Success requires a future-fit enterprise to address both sides of the profitability equation
Addressing the profitability equation
Closing thoughts
Meet the team
Aman Bajaaj
Managing Director – Asia Pacific Life Sciences Lead
Ramon Pressburger
Managing Director – North America Lead and Strategy Lead, Global Life Sciences
Visit our Subscription and Preference Center